Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong
· Delayed Price · Currency is HKD
17.69
-0.11 (-0.62%)
Mar 10, 2026, 3:53 PM HKT
HKG:3378 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Cash & Equivalents | 161.21 | 162 |
| Short-Term Investments | 12.67 | 42.36 |
| Cash & Short-Term Investments | 173.88 | 204.36 |
| Cash Growth | -14.92% | - |
| Prepaid Expenses | 68.91 | 93.9 |
| Other Current Assets | - | 0.5 |
| Total Current Assets | 242.79 | 298.76 |
| Property, Plant & Equipment | 24.13 | 24 |
| Long-Term Investments | 233.78 | 262.39 |
| Other Intangible Assets | 0.45 | 0.56 |
| Other Long-Term Assets | 0.33 | 0.53 |
| Accounts Payable | 12.29 | 12.94 |
| Accrued Expenses | 2.8 | 2.56 |
| Current Portion of Leases | 3.17 | 3.2 |
| Current Income Taxes Payable | 7.98 | 7.07 |
| Other Current Liabilities | 171.2 | 37.11 |
| Total Current Liabilities | 197.44 | 62.87 |
| Long-Term Leases | 8.66 | 11.83 |
| Long-Term Deferred Tax Liabilities | 78.77 | 90.47 |
| Other Long-Term Liabilities | - | 101.49 |
| Common Stock | 11.79 | 9.53 |
| Retained Earnings | -72.38 | 0.53 |
| Comprehensive Income & Other | 226.83 | 258.07 |
| Total Common Equity | 166.24 | 268.13 |
| Minority Interest | 50.37 | 51.45 |
| Total Liabilities & Equity | 501.47 | 586.24 |
| Total Debt | 11.83 | 15.03 |
| Net Cash (Debt) | 162.05 | 189.33 |
| Net Cash Growth | -14.41% | - |
| Net Cash Per Share | 14.82 | 25.95 |
| Filing Date Shares Outstanding | 11.79 | 7.3 |
| Total Common Shares Outstanding | 11.79 | 7.3 |
| Working Capital | 45.35 | 235.89 |
| Book Value Per Share | 14.10 | 36.75 |
| Tangible Book Value | 165.79 | 267.57 |
| Tangible Book Value Per Share | 14.06 | 36.68 |
| Machinery | 5.14 | 4.1 |
| Construction In Progress | 2.66 | 6.41 |
| Leasehold Improvements | 8.2 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.